Skip to main content
Kolon TissueGene, Inc. logo

Kolon TissueGene, Inc. — Investor Relations & Filings

Ticker · 950160 ISIN · KR8840120008 LEI · 5493000SYYLC88FUL781 KO Manufacturing
Open in API
Filings indexed 288 across all filing types
Latest filing 2022-03-25 Director's Dealing
Country US United States of America
Listing KO 950160

About Kolon TissueGene, Inc.

https://www.tissuegene.com/

Kolon TissueGene, Inc. is a clinical-stage biopharmaceutical company specializing in the development of advanced cell and gene therapies for orthopedic diseases and degenerative disorders. The company's lead product candidate, TG-C, is a first-in-class, allogeneic cell and gene therapy designed to treat knee osteoarthritis. The therapy aims to reduce pain, improve joint function, and slow the progression of the disease. TG-C is currently in late-stage clinical development, undergoing Phase 3 trials.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (often referred to as a 'Section 16' equivalent in the US) used to disclose insider trading or changes in share ownership by company directors and executives. Based on the provided definitions, this falls under 'Director's Dealing' (DIRS).
2022-03-25 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from Kolon TissueGene titled 'Audit Report Submission' (감사보고서 제출). It provides the audit opinion (unqualified/proper), key financial data (assets, liabilities, equity, profit/loss), and details regarding the auditor (Seohyun Accounting Corp). While it contains financial data, it is a specific regulatory disclosure of the audit report results rather than a full annual report (10-K) or a simple announcement of publication (RPA). It fits the definition of an Audit Report/Information (AR) as it provides the audit opinion and financial summary. FY 2021
2022-03-21 Korean
사업보고서 (2021.12)
Annual Report Classification · 100% confidence The document is a comprehensive 'Business Report' (사업보고서) for Kolon TissueGene, Inc. covering the fiscal year 2021 (2021.01.01-2021.12.31). It includes detailed sections on company overview, management, capital structure, and business operations, which are standard components of an annual report filed with regulatory bodies like the Financial Supervisory Service (FSS) and Korea Exchange (KRX). It is not an announcement of a report, but the report itself. FY 2021
2022-03-21 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Kolon TissueGene, Inc. It contains the agenda for the upcoming annual general meeting, including items such as the approval of financial statements, election of directors, and remuneration limits. This document is a formal proxy solicitation and information statement provided to shareholders to inform them of the meeting and request their votes, which aligns with the definition of a Proxy Solicitation & Information Statement (PSI).
2022-03-14 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Kolon TissueGene. It outlines the date, location, and agenda items (such as financial statement approval, director appointments, and remuneration limits) for the upcoming Annual General Meeting. This document serves as the official notification and solicitation of shareholder participation for the meeting, which falls under the Proxy Solicitation & Information Statement category.
2022-02-10 Korean
기타시장안내(코스닥시장위원회 개최 결과 및 심의속개 결정 안내)
Delisting Announcement Classification · 100% confidence The document is a short regulatory announcement from the Korea Exchange regarding the KOSDAQ Market Committee's decision to continue deliberations on the potential delisting of Kolon TissueGene. It does not contain full financial statements or a formal delisting notice, but rather an update on the regulatory status of the company's listing. As it is a regulatory announcement that does not fit into specific categories like 'Delisting Announcement' (which implies the final act of removal) or 'Legal Proceedings', it falls under the general regulatory filing category.
2022-02-07 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.